L 745870 Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413335

CAS#: 158985-00-3 (free base)

Description: L 745870 Free Base is a drug which acts as a dopamine receptor antagonist selective for the D₄ subtype, and has antipsychotic effects in animal models, though it was not effective in human trials.

Chemical Structure

L 745870 Free Base
CAS# 158985-00-3 (free base)

Theoretical Analysis

MedKoo Cat#: 413335
Name: L 745870 Free Base
CAS#: 158985-00-3 (free base)
Chemical Formula: C18H19ClN4
Exact Mass: 326.1298
Molecular Weight: 326.83
Elemental Analysis: C, 66.15; H, 5.86; Cl, 10.85; N, 17.14

Price and Availability

Size Price Availability Quantity
10.0mg USD 450.0 2 Weeks
Bulk inquiry

Related CAS #: 866021-03-6 (3HCl); 158985-00-3 (Free Base)  

Synonym: L 745870 Free Base; L745870; L-745870

IUPAC/Chemical Name: 3-((4-(4-Chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine


InChi Code: InChI=1S/C18H19ClN4/c19-15-3-5-16(6-4-15)23-10-8-22(9-11-23)13-14-12-21-18-17(14)2-1-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 326.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. Behav Pharmacol. 2015 Feb;26(1-2):101-8. doi: 10.1097/FBP.0000000000000096. PMID: 25303957.

2: Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther. 2012 Aug;342(2):576-85. doi: 10.1124/jpet.112.195693. Epub 2012 May 22. PMID: 22619253.

3: Baskerville TA, Allard J, Wayman C, Douglas AJ. Dopamine-oxytocin interactions in penile erection. Eur J Neurosci. 2009 Dec 3;30(11):2151-64. doi: 10.1111/j.1460-9568.2009.06999.x. Epub 2009 Nov 25. PMID: 20128851.

4: Marazziti D, Lucacchini A, Baroni S, Betti L, Catena M, Giannaccini G, Dell'Osso B, Masala I, Mungai F, Dell'Osso L. Presence of D4 dopamine receptors in human prefrontal cortex: a postmortem study. Braz J Psychiatry. 2007 Jun;29(2):148-52. doi: 10.1590/s1516-44462007000200011. PMID: 17639254.

5: Giorgioni G, Del Bello F, Pavletić P, Quaglia W, Botticelli L, Cifani C, Micioni Di Bonaventura E, Micioni Di Bonaventura MV, Piergentili A. Recent findings leading to the discovery of selective dopamine D4 receptor ligands for the treatment of widespread diseases. Eur J Med Chem. 2021 Feb 15;212:113141. doi: 10.1016/j.ejmech.2020.113141. Epub 2020 Dec 29. PMID: 33422983.

6: Gorelova N, Seamans JK, Yang CR. Mechanisms of dopamine activation of fast- spiking interneurons that exert inhibition in rat prefrontal cortex. J Neurophysiol. 2002 Dec;88(6):3150-66. doi: 10.1152/jn.00335.2002. PMID: 12466437.

7: Nakane M, Cowart MD, Hsieh GC, Miller L, Uchic ME, Chang R, Terranova MA, Donnelly-Roberts DL, Namovic MT, Miller TR, Wetter JM, Marsh K, Stewart AO, Brioni JD, Moreland RB. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist. Neuropharmacology. 2005 Jul;49(1):112-21. doi: 10.1016/j.neuropharm.2005.02.004. Epub 2005 Apr 1. PMID: 15992586.

8: Bristow LJ, Kramer MS, Kulagowski J, Patel S, Ragan CI, Seabrook GR. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci. 1997 Jun;18(6):186-8. doi: 10.1016/s0165-6147(97)01066-3. PMID: 9226994.

9: Jackson CR, Chaurasia SS, Zhou H, Haque R, Storm DR, Iuvone PM. Essential roles of dopamine D4 receptors and the type 1 adenylyl cyclase in photic control of cyclic AMP in photoreceptor cells. J Neurochem. 2009 Apr;109(1):148-57. doi: 10.1111/j.1471-4159.2009.05920.x. Epub 2009 Jan 22. PMID: 19166506; PMCID: PMC2727872.

10: Cheung TH, Bezzina G, Hampson CL, Body S, Fone KC, Bradshaw CM, Szabadi E. Effect of quinpirole on timing behaviour in the free-operant psychophysical procedure: evidence for the involvement of D2 dopamine receptors. Psychopharmacology (Berl). 2007 Aug;193(3):423-36. doi: 10.1007/s00213-007-0798-8. Epub 2007 May 6. PMID: 17484066.